文献速递生殖医学

芳香化酶抑制剂与他莫昔芬是否影响卵母细胞或胚胎冻存周期中获取的卵母细胞数量?

Do aromatase inhibitors and tamoxifen affect oocyte numbers retrieved in oocyte or embryo banking cycles?
PubMed 文献 · Reprod Biomed Online · 2024-11-04

该观察性队列研究基于2016至2018年SART CORS数据,纳入42,854例18-43岁接受卵母细胞或胚胎冻存周期的患者,比较使用芳香化酶抑制剂、他莫昔芬与未用辅助药物周期的获卵数。结果显示,未用药组获卵数及冻存卵数均高于芳香化酶抑制剂组;在性腺毒性治疗前冻存周期中,芳香化酶抑制剂组与用药组获卵数无差异;他莫昔芬组与未用药组在所有冻存周期中获卵数及冻存卵数均无差异。广义线性模型显示,在卵母细胞与胚胎冻存联合周期中,芳香化酶抑制剂组获卵数调整后均值显著低于未用药组。

要点

  • 未用药组获卵数14.2枚,高于芳香化酶抑制剂组12.6枚(P<0.001)。
  • 性腺毒性治疗前冻存周期中,芳香化酶抑制剂组与用药组获卵数无差异。
  • 他莫昔芬组与未用药组在所有冻存周期中获卵数及冻存卵数均无差异。

核心结论

  • 使用芳香化酶抑制剂的冻存周期在非性腺毒性治疗指征下可能损害获卵数。
  • 数据支持在性腺毒性治疗前冻存周期中继续使用芳香化酶抑制剂,因IVF周期结局和活产率与未用药周期相当。

研究设计与样本

  • 观察性队列研究,纳入2016至2018年SART CORS中年龄18-43岁接受卵母细胞或胚胎冻存周期的患者,共42,854例。
  • 分析的新鲜冻存周期包括:卵巢刺激方案中使用芳香化酶抑制剂者2096例、他莫昔芬者58例、未用辅助药物者40,700例。
  • 周期启动时平均年龄35岁;大多数患者为未孕(77.31%)和未产(91.76%)。

主要发现

  • 所有冻存周期中,未用药组平均获卵数和冻存卵数均高于芳香化酶抑制剂组(获卵数:14.2 vs 12.6,P<0.001;冻存卵数:11.4 vs 10.3,P<0.001)。
  • 在性腺毒性治疗前冻存周期中,芳香化酶抑制剂组与用药组获卵数无差异;他莫昔芬组与未用药组在所有冻存周期中获卵数及冻存卵数均无差异。
  • 广义线性模型中,卵母细胞与胚胎冻存联合周期中,芳香化酶抑制剂组获卵数调整后均值差异显著低于未用药组(-1.25,95%CI -1.7至-0.80;P<0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RESEARCH QUESTION: Does the number of oocytes retrieved differ in oocyte and embryo banking cycles using tamoxifen versus aromatase inhibitors versus no adjuvant medications? DESIGN: Observational cohort study of patients (n = 42,854) aged 18-43 years undergoing oocyte or embryo banking cycles between 2016 and 2018 recorded in SART CORS. RESULTS: The following fresh banking cycles were analysed: oocyte and embryo banking cycles using, as part of the ovarian stimulation protocol, aromatase inhibitors (n = 2096); tamoxifen (n = 58) and no adjuvant medications (n = 40,700). Mean age at cycle initiation was 35 years; most patients were nulligravid (77.31%) and nulliparous (91.76%). Mean numbers of oocytes retrieved and cryopreserved in all banking cycles were higher in the no adjuvant medication group compared with the aromatase inhibitor group (oocytes retrieved: 14.2 versus 12.6; P < 0.001; oocytes cryopreserved: 11.4 versus 10.3; P < 0.001); no difference was observed in oocyte yield between the aromatase inhibitors and adjuvant medication groups in banking cycles before gonadotoxic treatment, nor in the number of oocytes retrieved or cryopreserved between the tamoxifen and no adjuvant medication groups in all banking cycles. In the generalized linear model, the adjusted mean difference of oocytes retrieved was significantly lower in the aromatase inhibitor group compared with the no adjuvant medication group (-1.25, 95% CI -1.7 to -0.80; P < 0.001) in combined oocyte and embryo banking cycles. CONCLUSION: Banking cycles using aromatase inhibitors may compromise oocyte yield when used for cycles without a pre-gonadotoxic treatment indication. Our data support the continued use of aromatase inhibitors for pre-gonadotoxic treatment banking cycles as IVF cycle outcomes and live birth rates are comparable to those for cycles with no adjuvant medication.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Sauerbrun-Cutler MT, Klein EJ, Scarpaci MM, et al. Do aromatase inhibitors and tamoxifen affect oocyte numbers retrieved in oocyte or embryo banking cycles? Reprod Biomed Online. 2024. PMID: 40532313. doi:10.1016/j.rbmo.2024.104699

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。